Comparative Pharmacology
Head-to-head clinical analysis: METATENSIN 2 versus SERPASIL ESIDRIX 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METATENSIN 2 versus SERPASIL ESIDRIX 1.
METATENSIN #2 vs SERPASIL-ESIDRIX #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.
Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.
1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.
None Documented
None Documented
12 hours (terminal); clinical context: twice-daily dosing maintains stable plasma levels
Reserpine: 50-100 hours (terminal); clinical effects persist due to irreversible adrenergic neuron blockade. Hydrochlorothiazide: 6-15 hours (terminal).
Renal (80% unchanged, 15% as glucuronide metabolite); biliary/fecal (5%)
Reserpine: renal (30% as metabolites, <1% unchanged), fecal (60% as metabolites). Hydrochlorothiazide: renal (>95% unchanged).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination